Torren Management’s Castle Biosciences CSTL Stock Holding History

Torren Management’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-21	Closed	-$817	–	1110
2025 Q4	$817	Buy	+21	New	+$677	﹤0.01%	1234

Other funds holding CSTL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Torren Management's CSTL Position: Q1 2026 in Review

Torren Management sold out of Castle Biosciences (CSTL) in Q1 2026, closing a stake of 21 shares — an estimated $817 sold.

Torren Management first reported a position in CSTL in Q4 2025 and held it in 1 quarter. The position peaked at $817 in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

Torren Management reported no remaining Castle Biosciences position as of Q1 2026 after selling out during the quarter.
Torren Management sold 21 Castle Biosciences shares in Q1 2026, an estimated $817.
Torren Management first reported a position in Castle Biosciences in Q4 2025 and held it in 1 quarter.
Torren Management's Castle Biosciences position peaked at $817 in Q4 2025.
186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.